{
  "id": 5416,
  "text": "Available at: http://www.ncbi.nlm.nih.gov/pubmed/19720909.235.Tewari KS, Sill MW, Penson RT, et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Available at: http://www.ncbi.nlm.nih.gov/pubmed/19720909.235.Tewari KS, Sill MW, Penson RT, et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在治疗晚期宫颈癌方面，贝伐珠单抗（Bevacizumab）是一个值得关注的药物。临床研究表明，与标准化疗联合使用贝伐珠单抗后，可以改善晚期宫颈癌患者的总体生存率。这种治疗方案也伴随了一些不良事件，但整体效果显示出较好的生存收益。因此，贝伐珠单抗结合化疗已经成为晚期宫颈癌治疗的重要选项之一。对于晚期宫颈癌患者，该药物的使用和相关试验结果是非常值得关注的。",
  "query": "在治疗晚期宫颈癌方面，有哪些药物的临床试验结果值得关注？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗晚期宫颈癌方面，有哪些药物的临床试验结果值得关注？\n\n<reference text>: Available at: http://www.ncbi.nlm.nih.gov/pubmed/19720909.235.Tewari KS, Sill MW, Penson RT, et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在治疗晚期宫颈癌方面，贝伐珠单抗（Bevacizumab）是一个值得关注的药物。临床研究表明，与标准化疗联合使用贝伐珠单抗后，可以改善晚期宫颈癌患者的总体生存率。这种治疗方案也伴随了一些不良事件，但整体效果显示出较好的生存收益。因此，贝伐珠单抗结合化疗已经成为晚期宫颈癌治疗的重要选项之一。对于晚期宫颈癌患者，该药物的使用和相关试验结果是非常值得关注的。"
}